PETX News and Press, Aratana Therapeutics Inc. From 06/19/19

Merck's ( MRK +1.1% ) reported interest in small and medium-sized deals in animal health medicine, among other areas, appears to be driving gains for some names in the space: HSKA +3% , TRUP +3% , PETQ +2.3% , PETX +1.3% , ELAN +1% . More news on: Merck & Co., Inc., ...

LEAWOOD, Kan. , June 11, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the U.S. Food and Drug Administration's Center for Veteri...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 108 weeks of public selections as part of this ongoing live forward-testing. In...

LEAWOOD, Kan. , June 7, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting results for the four proposals considered and v...

The following slide deck was published by Aratana Therapeutics, Inc. in conjunction with this Read more ...

I've taken the M&A dashboard as a base to quickly review the most interesting M&A deals that are ongoing. I've highlighted the deals that I think are interesting and where I had/have/consider a position and briefly discuss them below. Here's are the first few rows of the dashboard with...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 105 weeks of public selections as part of this ongoing live forward-testing. In...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 104 weeks of public selections as part of this ongoing live forward-testing. ...

Aratana Therapeutics (NASDAQ: PETX ): Q1 GAAP EPS of -$0.14 misses by $0.03 . Revenue of $7.4M (+83.2% Y/Y) beats by $0.6M . Press Release More news on: Aratana Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,

LEAWOOD, Kan. , May 8, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, announced its first quarter 2019 financial results and recent business high...